ERBB2 and neoplasm: From a precision oncology standpoint, two molecular alterations in this patient’s tumor impacted the course of her care – the finding of p53 mutant immunohistochemistry after initial resection and the ERBB2 amplification, suggesting that evaluation for these alterations may be useful to guide clinical decision making.